A First-in-Human Study of AV-001 in Healthy Subjects
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple
ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability
assessments will be conducted, and blood samples will be taken pre-dose and at several time
points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.